Sihuan Pharmaceutical Holdings

0460 · HKEX · China

Public Market Listing

0460HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Sihuan Pharmaceutical Holdings are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
janagliflozin(Huiyoujing)
Phase 3
SGLT2Small molecule
Type 2 DiabetesChronic Kidney Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 June 2025Filing acceptedXZP-3287NMPA accepts bireociclib NDA for a third indication
CN, NMPA · Sihuan Pharmaceutical Holdings Group · Source ↗
2 May 2024Filing acceptedXZP-3621NMPA accepts NDA for dexitinib (XZP-3621)
CN, NMPA · Sihuan Pharmaceutical Holdings Group Ltd. · Source ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$158M$21M$455M—report ↗

Sihuan Pharmaceutical Holdings reported revenue of $158.16M, R&D spend of $21.08M, and cash and equivalents of $454.72M for H1 2025.

Figures only: this period's report disclosed no narrative text

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$364M$41M$509M—report ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$265M$66M$483M—report ↗
2023-FY$263M$82M$532M—report ↗
2022-FY$325M$139M$550M—report ↗
2021-FY$471M$135M$892M—report ↗